BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vasa Therapeutics VS-041 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vasa Therapeutics VS-041\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07219511-643@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Vasa Therapeutics VS-041: Phase 1 readout est. (NCT07219511)
DESCRIPTION:Vasa Therapeutics VS-041\, phase 1\, Heart Failure.\nStudy: A S
 afety\, Tolerability\, and Biomarker Trial of VS-041 in Participants With 
 Heart Failure With Preserved Ejection Fraction (HFpEF)\nEstimated primary 
 completion: November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/vasa-therapeutics-vs-041#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07219511
URL:https://assetmemo.bio/drug/vasa-therapeutics-vs-041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
